.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Moodys
US Department of Justice
McKinsey
UBS
Fish and Richardson
Fuji
Healthtrust
Baxter

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022474

« Back to Dashboard

NDA 022474 describes ELLA, which is a drug marketed by Lab Hra Pharma and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ELLA profile page.

The generic ingredient in ELLA is ulipristal acetate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ulipristal acetate profile page.

Summary for 022474

Tradename:1
Applicant:1
Ingredient:1
Patents:5

Pharmacology for NDA: 022474

Suppliers and Packaging for NDA: 022474

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELLA ulipristal acetate TABLET;ORAL 022474 NDA Afaxys Pharma LLC 50102-911 50102-911-01 1 BLISTER PACK in 1 CARTON (50102-911-01) > 1 TABLET in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength30MG
Approval Date:Aug 13, 2010TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jun 12, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
Patent:► SubscribePatent Expiration:Jun 2, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Feb 20, 2029Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Citi
Dow
Daiichi Sankyo
Cerilliant
McKinsey
Baxter
US Army
Federal Trade Commission
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot